TONIX PHARMACEUTICALS HOLDING CORP. Net Fee Amt
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) had Net Fee Amt of $2.82 thousand as of 2026-07-01, per its S-8 filed 2026-07-01.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-07-01
- 2026-07-01: Net Fee Amt $2.82K.
| Period end | Net Fee Amt |
|---|---|
| 2026-07-01 | $2.82K S-8 · filed 2026-07-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |